Why the study?
Does low-dose neuroleptic therapy reduce extrapyramidal side effects in schizophrenic patients?
Does low-dose neuroleptic therapy reduce extrapyramidal side effects in schizophrenic patients?
Low-dose neuroleptic therapy provides only a limited reduction in extrapyramidal side effects compared to standard-dose therapy in schizophrenia.
Answers are grounded in this paper and cite their sources.
Low-dose neuroleptics yield only modest EPS reduction; supports individualized dosing but leaves antipsychotic efficacy unaddressed.
A meta-analysis of the published literature was performed in order to quantify the efficacy of low-dose neuroleptic therapy in reducing extrapyramidal side effects in schizophrenic patients. A low-dose regimen between 50-100 mg equivalents of chlorpromazine, in comparison to a standard-dose regimen between 200-500 mg reduced extrapyramidal side effects by a 0.30 (+/-0.12) standard deviation, which is only a limited effect.
No takes yet. Share an insight, caveat, or question.
Barbui et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: